| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |